August 29, 2026
RESEARCH USE ONLY. Retatrutide is an investigational compound and is not approved by the FDA for human or veterinary use. Products discussed on this site are supplied strictly for laboratory and research purposes. Nothing on this page is medical advice or a dosing recommendation for any person or animal.
Most explanations of retatrutide stop at “it hits three receptors.” That is true and almost useless — it does not tell you which three, in what proportion, or why the proportion is the interesting part. The receptor ratio is the whole design decision, and it is measurable.
Sourced fact: Retatrutide (development code LY3437943) is described by its discovery team as “a novel triple agonist peptide at the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).” The same paper states: “In vitro, LY3437943 shows balanced GCGR and GLP-1R activity but more GIPR activity.” [1]
Inference: “Triple agonist” is therefore a description of targets, not of equal engagement. The molecule is deliberately imbalanced, and understanding it means understanding which way it leans.
Sourced fact: A 2024 structural study in Cell Discovery reports: “Compared to the corresponding endogenous hormones, retatrutide is more potent at GIPR by a factor of 8.9, and less potent at GCGR and GLP-1R by factors of 0.3 and 0.4, respectively.” [2]
| Receptor | Potency relative to the native hormone |
|---|---|
| GIPR | ~8.9× native GIP |
| GLP-1R | ~0.4× native GLP-1 |
| GCGR | ~0.3× native glucagon |
Inference: Read as a ratio rather than three separate numbers, retatrutide is roughly a twenty-fold-plus GIPR-leaning molecule relative to its GLP-1R and GCGR activity. That is the single most defining pharmacological fact about it.
What we could not verify: absolute EC50 or pEC50 values. The Cell Discovery paper reports relative potencies only, and the original discovery paper’s potency table sits behind a paywall we did not retrieve. Any page quoting specific picomolar EC50 figures for retatrutide is citing that paywalled table. We are not reproducing numbers we could not read.
Sourced fact: “GLP-1 activates the GLP-1R to stimulate adenylate cyclase (AC), increasing intracellular levels of cyclic AMP (cAMP),” and “cAMP signaling stimulates PKA and EPAC, both of which contribute to the production and release of insulin.” [3]
Sourced fact: The GLP-1 receptor “is broadly distributed across various organs and tissues, including but not limited to the brain, heart, kidneys, intestines, eyes, and the vascular system.” [3]
Sourced fact: GIPR expression is documented in “adipose tissue, stomach, bone, adrenal cortex, heart, pituitary, endothelial cells, testis,” and across CNS regions including “the arcuate nucleus (ARH) and dorsomedial nucleus (DMH) of the hypothalamus” and “the area postrema (AP) and nucleus tractus solitarius (NTS) of the brainstem.” [4]
Sourced fact: Whether GIPR agonism or antagonism produces metabolic benefit is genuinely unresolved. A 2025 review in Diabetes frames it directly: “The conundrum that we attempt to resolve is how two diametrically opposing pharmacological approaches can produce the same outcome of reducing body weight.” [5] A separate 2025 review states that “the fundamental question of whether to agonize or antagonize GIPR to treat obesity remains unanswered.” [6]
Inference: This is worth sitting with. Retatrutide’s most pronounced activity is at a receptor where the field has not settled which direction of engagement is beneficial. That is not a criticism of the molecule — it is a description of where the science is. We cover this in detail in our GLP-1 vs GIP explainer.
Sourced fact: The discovery paper’s stated rationale: “Body weight loss was augmented by the addition of GCGR-mediated increases in energy expenditure to GIPR- and GLP-1R-driven calorie intake reduction.” [1]
Sourced fact: A 2025 review reports that “Gcg enhances energy expenditure, mediated in part by the activation of brown adipose tissue and thermogenesis,” and that “Gcg enhances lipolysis by promoting lipid oxidation.” The same review states plainly that “specific data on dual GLP-1/Gcg RAs… are currently limited” and that “long-term safety data are currently lacking, representing a critical gap.” [7]
Sourced fact: The evidence is not uniformly supportive. A 2022 review sympathetic to the thermogenic hypothesis nonetheless records that “sub-chronic administration of glucagon (72-hours) failed to impact energy utilization.” [8]
Inference: The glucagon arm is the mechanistically distinctive part of the design and also the least clinically settled. Adding energy expenditure to appetite suppression is the hypothesis; the human evidence for the expenditure contribution specifically is preliminary.
Sourced fact: In the Phase 2 obesity trial, 338 adults were randomised to retatrutide or placebo for 48 weeks. “At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.” [9]
Sourced fact: The same abstract reports: “The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.” [9]
What we could not verify: the NEJM abstract contains no confidence intervals and no numeric adverse-event frequencies. Pages quoting “−24.2% (95% CI …)” attributed to that abstract are quoting something that is not in it.
Sourced fact: A body-composition substudy of the Phase 2 diabetes trial is the one retatrutide publication we found reporting true confidence intervals: least-squares mean change in total fat mass versus placebo was “−21.6 (−27.1 to −16.1, p<0.0001) with retatrutide 8 mg (pooled).” [10]
Sourced fact: “Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.” [9]
Inference: This is the finding most often omitted from summaries of retatrutide, and it is mechanistically consistent with glucagon receptor engagement. Reporting a compound’s pharmacology honestly means reporting the signals that are not favourable alongside the ones that are.
This is not medical advice, not a protocol, and not a starting point for administration to any person or animal. It describes receptor pharmacology and reports what published trials measured, as those documents state it. Where the literature is unsettled — GIPR direction, glucagon’s contribution to human energy expenditure — we have said so rather than smoothing it over.
Retatrutide is not FDA approved. See our page on retatrutide’s regulatory status for the sourced detail.
PureLab Performance supplies retatrutide for laboratory research use. Every compound page publishes its own specification block — lot, chromatographic purity, label claim, identity method and testing laboratory — or states plainly that the certificate is pending. In a literature where the receptor ratio is the defining property, knowing exactly what is in the vial is not a detail.
RESEARCH USE ONLY — FULL DISCLAIMER. The products discussed on this page are supplied strictly for laboratory and scientific research purposes. They are not for human or veterinary use, and not for consumption. These statements have not been evaluated by the Food and Drug Administration. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease in humans or animals. Nothing here constitutes medical or veterinary advice or a dosing, preparation, or administration recommendation for any person or animal.
